PerkinElmer, Inc. and Invitrogen Corporation have announced a co-marketing partnership that will provide pharmaceutical and biotechnology companies with an integrated solution for high throughput cellular screening of ion channels, which are critical therapeutic targets implicated in many human physiological roles and for drug safety testing.
This collaboration creates a rapid, reproducible and reliable platform for ion-channel drug discovery, replacing or improving previous studies which were limited to slow, non-robust and labor intensive methods.
Under the terms of the agreement, Invitrogen’s Voltage Sensor Probes (VSP) ion channel reagents will be combined with PerkinElmer’s CellLux™ Fluorescence Cellular Screening Platform.
CellLux is an automated cellular workstation designed for cellular screening with sophisticated and sensitive ratiometric detection.
It complements PerkinElmer’s ViewLux™ ultraHTS Microplate Imager and the LumiLux ™ flash and glow Luminescence Cellular Screening Platform in lead discovery by enabling live cell kinetic ion channel screening.
Invitrogen’s Voltage Sensitive Probe reagents are ratiometric dyes that are designed to offer superior assay performance, accuracy and stability for even the most demanding ion channel applications.
The ratiometric capabilities of both platforms combine to form a solution for ion channel discovery and development programs.
The CellLux is designed to provide integrated liquid handling, data presentation and analysis software which contribute to its performance, utility and robustness.
“With the pharmaceutical industry’s increased pressure to fill drug pipelines with more effective drug targets, this partnership will help our customers in transitioning to cellular screening, to drive fundamental productivity improvements into the drug discovery and development process,” said Peter Coggins, PhD., president, PerkinElmer Life and Analytical Sciences.
"This latest partnership is consistent with our strategy for expanding our cellular sciences portfolio, enabling drug companies to adopt more predictive and productive methodologies to increase their downstream success rates and allow drug candidates to get to the clinic sooner.”
“The combination of PerkinElmer’s versatile CellLux Platform and our VSP ion channel reagents has set a new standard for assay development and high throughput cellular screening that will allow drug makers to provide more effective drugs faster, without sacrificing quality or cost,” said Nick Ecos, Vice President and General Manager of Invitrogen Corporation’s Drug Discovery Solutions business.
“We will continue to pair our technologies with those from industry-leading companies like PerkinElmer in order to capitalize on our integrated strength.”